Original ArticlesEfficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Key Words
Cited by (0)
Dr. Hoffknecht has participated in boards for Lilly Oncology and has received institutional grant support and compensation for travel expenses from Boehringer Ingelheim. Dr. Tufman has received compensation for lectures from Boehringer Ingelheim, Eli Lilly, Roche, and Novartis. Dr. Wehler has served as consultant and participated in boards and has received compensation for lectures and educational presentations from Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, and Bristol-Myers Squibb. Dr. Wiewrodt has participated in investigator-initiated trials for Bayer and Eli Lilly and advisory boards for Boehringer Ingelheim Grifols, Eli Lilly, Novartis, Roche, and Talecris. Dr. Wiewrodt has also received compensation for lectures and CME from Bayer, Boehringer Ingelheim, EuMeCom, Grifols, GlaxoSmithKline, Eli Lilly, MSD, Novartis, Pfizer, Roche, Talecris, UKM Academy, and ZDF. Dr. Schütz has participated in advisory boards for Boehringer Ingelheim. Dr. Serke has participated in boards and received compensation for lectures from Boehringer Ingelheim, Eli Lilly, Pfizer, and Roche and has received honoraria for participation in review activities from Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, and Amgen. Dr. Stöhlmacher-Williams has served as consultant and received compensation for lectures and previous manuscript preparation from Boehringer Ingelheim. Dr. Märten is a full-time employee of Boehringer Ingelheim Pharma GmbH & Co KG. Dr. Huber has served as consultant for Boehringer Ingelheim and has received compensation for lectures from Boehringer Ingelheim, Pfizer, and Pierre Fabre Pharma GmbH. Dr. Dickgreber has participated in boards for Boehringer Ingelheim, Eli Lilly, Roche, Novartis, and Bristol-Myers Squibb and has served as consultant and provided expert testimony for Boehringer Ingelheim, Eli Lilly, and Roche. Dr. Pelzer declares no conflicts of interest.
- 1
Drs. Hoffknecht and Tufman contributed equally to this work.
- ‡‡
Members of the Afatinib Compassionate Use Consortium (ACUC) are listed in Appendix